Capital BlueCross Drug Formulary & Utilization Management Updates: July 1, 2015

Capital’s November 2014 and February 2015 decisions from recent P&T Committee meetings resulted in updates made to the open/closed and selectively closed formulary.  Effective July 1, 2015 additional updates have been made to the Formulary & Utilization Management.

Updates included:

  •  Newly Marketed Drugs
  •  Products Changing Tier Status
  •  Pharmacy Utilization Management Programs

July 1, 2015 changes of note:

  •  Nasal steroids will require prior authorization
  •  Victrelis will be moving from brand preferred to brand non-preferred

July 1, 2015 CBC Drug Formulary & Utilization Management Updates

DISCLOSURE

The information provided herein is intended solely for the use of our clients. You may not display, reproduce, copy, modify, license, sell or disseminate in any manner any information included herein, without the express permission of the Publisher or Publishers of articles within.

The information provided is for informational purposes only and does not constitute legal advice. The information above contains only a summary of the applicable legal provisions and does not purport to cover every aspect of any particular law, regulation or requirement. Depending on the specific facts of any situation, there may be additional or different requirements. This is to be used only as a guide and not as a definitive description of your compliance obligations.